TXG

MKT CAP:$3B

10x Genomics, Inc.

Market Cap

$3B

Healthcare·Medical - Healthcare Information Services·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$21.98+$5.36 (+32.25%)

Apr 24, 2026

Company Details

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company pr...

CEO

Serge Saxonov

IPO Date

Sep 12, 2019

Website

www.10xgenomics.com

Key Metrics TTM

Revenue

$643M

+5.2% YoY

Net Income

-$44M

EPS (Diluted)

-$0.35

Free Cash Flow

$130M

Revenue / Share

$5.06

Gross Margin

69.1%

Operating Margin

-9.5%

Net Margin

-6.8%

FCF Margin

20.2%

P/S

4.4x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Feb 12, 2026

$643M+5.2%EPS -$0.35

Q4 2025

Feb 12, 2026

$166M+0.6%EPS -$0.13

Q3 2025

Nov 6, 2025

$149M-1.7%EPS -$0.22

Q2 2025

Aug 7, 2025

$173M+12.9%EPS $0.28

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$114M	$89M	-$42M
Q2 22	$115M	$87M	-$63M
Q3 22	$131M	$101M	-$40M
Q4 22	$156M	$119M	-$23M
Q1 23	$134M	$98M	-$52M
Q2 23	$147M	$100M	-$63M
Q3 23	$154M	$96M	-$95M
Q4 23	$184M	$116M	-$55M
Q1 24	$141M	$93M	-$61M
Q2 24	$153M	$104M	-$42M
Q3 24	$152M	$106M	-$41M
Q4 24	$165M	$111M	-$50M
Q1 25	$155M	$105M	-$39M
Q2 25	$173M	$125M	$30M
Q3 25	$149M	$100M	-$32M
Q4 25	$166M	$113M	-$20M

Valuation

Quarter	P/S	P/E
Q1 22	15.9x	—
Q2 22	11.2x	—
Q3 22	6.5x	—
Q4 22	9.0x	—
Q1 23	11.7x	—
Q2 23	11.8x	—
Q3 23	8.1x	—
Q4 23	10.3x	—
Q1 24	7.1x	—
Q2 24	3.6x	—
Q3 24	4.4x	—
Q4 24	2.9x	—
Q1 25	1.7x	—
Q2 25	2.3x	—
Q3 25	2.2x	—
Q4 25	3.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$21M	-$49M
Q2 22	-$17M	-$44M
Q3 22	-$10M	-$46M
Q4 22	$14M	-$26M
Q1 23	-$4M	-$9M
Q2 23	-$12M	-$37M
Q3 23	-$25M	-$41M
Q4 23	$26M	$22M
Q1 24	-$16M	-$19M
Q2 24	$7M	$4M
Q3 24	$22M	$18M
Q4 24	-$7M	-$9M
Q1 25	$34M	$32M
Q2 25	$18M	$16M
Q3 25	$43M	$43M
Q4 25	$41M	$39M

Capital Expenditures

Quarter	CapEx
Q1 22	$28M
Q2 22	$27M
Q3 22	$37M
Q4 22	$40M
Q1 23	$5M
Q2 23	$25M
Q3 23	$15M
Q4 23	$3M
Q1 24	$3M
Q2 24	$4M
Q3 24	$4M
Q4 24	$3M
Q1 25	$2M
Q2 25	$2M
Q3 25	$687.0K
Q4 25	$2M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+8.2%	+34.6%
Q2 22	-1.1%	+40.9%
Q3 22	+4.6%	+21.2%
Q4 22	+8.8%	+12.5%
Q1 23	+17.3%	+19.2%
Q2 23	+28.1%	+18.3%
Q3 23	+17.2%	+45.2%
Q4 23	+17.8%	+33.4%
Q1 24	+5.0%	+8.7%
Q2 24	+4.3%	-7.3%
Q3 24	-1.3%	-22.3%
Q4 24	-10.3%	-10.2%
Q1 25	+9.8%	-4.1%
Q2 25	+12.9%	-26.7%
Q3 25	-1.7%	-6.2%
Q4 25	+0.6%	-13.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$26M	22.7%
Q2 22	$36M	31.7%
Q3 22	$34M	25.6%
Q4 22	$41M	26.2%
Q1 23	$42M	31.4%
Q2 23	$46M	31.1%
Q3 23	$40M	26.2%
Q4 23	$39M	21.2%
Q1 24	$36M	25.6%
Q2 24	$38M	25.1%
Q3 24	$34M	22.1%
Q4 24	$33M	19.7%
Q1 25	$31M	20.1%
Q2 25	$28M	15.9%
Q3 25	$25M	17.0%
Q4 25	$25M	15.2%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$64M	—	—	$67M
Q2 22	$71M	—	—	$79M
Q3 22	$67M	—	—	$73M
Q4 22	$64M	$75M	$4M	—
Q1 23	$67M	—	—	$83M
Q2 23	$71M	—	—	$92M
Q3 23	$108M	—	—	$82M
Q4 23	$65M	—	—	$86M
Q1 24	$69M	—	—	$86M
Q2 24	$63M	—	—	$83M
Q3 24	$66M	—	—	$82M
Q4 24	$67M	$90M	$4M	—
Q1 25	$64M	—	—	$90M
Q2 25	$61M	—	—	$74M
Q3 25	$57M	—	—	$75M
Q4 25	$56M	—	—	$77M

Revenue Segments

Quarter	Consumables	Instruments	Service
Q1 22	$98M	$14M	$2M
Q2 22	$98M	$15M	$2M
Q3 22	$108M	$21M	$2M
Q1 23	$112M	$19M	$3M
Q2 23	$112M	$31M	$3M
Q3 23	$114M	$35M	$4M
Q4 23	$140M	$38M	$5M
Q1 24	$110M	$25M	$5M
Q2 24	$123M	$24M	$6M
Q3 24	$126M	$19M	$6M

Revenue by Geography

Quarter	Americas, Excluding United States	Asia-Pacific, Excluding China	China	Emea	United States	Americas
Q1 22	$2M	$14M	$21M	$21M	$57M	—
Q2 22	$2M	$9M	$9M	$26M	$69M	—
Q3 22	$2M	$10M	$16M	$28M	$75M	—
Q4 22	$3M	$14M	$14M	$43M	$83M	—
Q1 23	—	$13M	$14M	$28M	—	$79M
Q2 23	—	$11M	$13M	$31M	—	$92M
Q3 23	—	$10M	$12M	$32M	—	$99M
Q4 23	—	$18M	$12M	$51M	—	$104M
Q1 24	—	$13M	$14M	$35M	—	$80M
Q2 24	—	$9M	$14M	$37M	—	$93M
Q3 24	—	$11M	$15M	$38M	—	$88M
Q4 24	—	$13M	$15M	$50M	—	$87M
Q1 25	—	$16M	$17M	$32M	—	$91M
Q2 25	—	$9M	$23M	$35M	—	$106M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$312M	$227M	$539M
Q2 22	$274M	$226M	$500M
Q3 22	$234M	$218M	$452M
Q4 22	$220M	$210M	$430M
Q1 23	$332M	$86M	$418M
Q2 23	$326M	$66M	$391M
Q3 23	$311M	$46M	$357M
Q4 23	$359M	$29M	$389M
Q1 24	$356M	$16M	$372M
Q2 24	$380M	$269.0K	$380M
Q3 24	$398M	$0	$398M
Q4 24	$344M	$49M	$393M
Q1 25	$377M	$50M	$427M
Q2 25	$398M	$50M	$447M
Q3 25	$433M	$50M	$482M
Q4 25	$474M	$49M	$523M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	113M	+1.0%	+3.9%
Q2 22	114M	+0.5%	+3.4%
Q3 22	114M	+0.5%	+2.9%
Q4 22	115M	+0.6%	+2.6%
Q1 23	116M	+0.8%	+2.3%
Q2 23	117M	+0.9%	+2.8%
Q3 23	118M	+0.9%	+3.2%
Q4 23	119M	+0.7%	+3.3%
Q1 24	119M	+0.7%	+3.3%
Q2 24	120M	+0.6%	+2.9%
Q3 24	121M	+0.6%	+2.6%
Q4 24	122M	+0.7%	+2.6%
Q1 25	123M	+0.8%	+2.7%
Q2 25	125M	+1.6%	+3.7%
Q3 25	126M	+0.8%	+4.0%
Q4 25	127M	+1.3%	+4.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$246.8K	464
Q2 22	$247.0K	464
Q3 22	$282.5K	464
Q4 22	$348.7K	448
Q1 23	$299.7K	448
Q2 23	$327.7K	448
Q3 23	$343.0K	448
Q4 23	$407.9K	451
Q1 24	$312.7K	451
Q2 24	$339.5K	451
Q3 24	$336.3K	451
Q4 24	$126.4K	1K
Q1 25	$118.6K	1K
Q2 25	$132.4K	1K
Q3 25	$114.1K	1K
Q4 25	$140.9K	1K

Revenue / Employee